The Effect of Morphine on Prasugrel Absorption in STEMI Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01536964

Enrollment

Registered

2012-02-22

Start date

2012-04-30

Completion date

2013-03-31

Last updated

2022-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Brief summary

Heart Attacks are a major cause of death in this country. When patients have a heart attack, they are treated with anti-clotting drugs, one of which is a drug called Prasugrel. It is important that Prasugrel starts to work as quickly as possible following a heart attack. As many patients who have a heart attack experience excruciating pain, they are often given morphine (a strong painkiller) by the Ambulance crew. We think that morphine may affect how Prasugrel is absorbed from the stomach and may delay how quickly it starts to work. We intend to study the effect of morphine on the absorption of Prasugrel.

Interventions

DRUGmorphine

2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later

DRUGsaline

2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* \>18 years of age and willing and able to provide informed consent * Admission to hospital with a STEMI \>12 months prior to recruitment * Previous prasugrel and morphine use with no adverse effect

Exclusion criteria

* Active respiratory disorder, resting oxygen saturation \< 95% or decompensated congestive cardiac failure * Current use of anti-platelet or anti-coagulant drugs apart from aspirin 75 mg daily, or receipt of any dose of clopidogrel, prasugrel or ticagrelor in the last 2 weeks * Current use of opiate analgesia

Design outcomes

Primary

Measure	Time frame	Description
VerifyNow P2Y12 PRU measurement at 2 hours post dose	2 hours	Assessment of platelet function

Secondary

Measure	Time frame	Description
Estimated time to PRU less than 150; maximal LTA response to ADP 20 microM at 2 hours post dose; final LTA response to ADP 5 microM at 2 hours post dose.	2 hours	further assessment of platelet function

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026